Publicacións en colaboración con investigadores/as de St. Michael's Hospital (13)

2024

  1. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial

    Circulation: Cardiovascular Interventions, Vol. 17, Núm. 6, pp. 457-473

2023

  1. Survival after Invasive or Conservative Management of Stable Coronary Disease

    Circulation, Vol. 147, Núm. 1, pp. 8-19

2022

  1. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

    Nature Medicine, Vol. 28, Núm. 12, pp. 2512-2520

  2. Transcatheter aortic valve replacement in obese patients: procedural vascular complications with the trans-femoral and trans-carotid access routes

    Interactive cardiovascular and thoracic surgery, Vol. 34, Núm. 6, pp. 982-989

  3. Transcatheter versus surgical aortic valve replacement in patients with morbid obesity: a multicentre propensity score-matched analysis

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 18, Núm. 5, pp. e417-e427

2021

  1. Empagliflozin in heart failure with a preserved ejection fraction

    New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461

  2. Impact of morbid obesity and obesity phenotype on outcomes after transcatheter aortic valve replacement

    Journal of the American Heart Association, Vol. 10, Núm. 12

  3. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

2020

  1. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

    European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  2. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine

    American Journal of Cardiovascular Drugs, Vol. 19, Núm. 2, pp. 173-183

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

2012

  1. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada

    European Journal of Preventive Cardiology, Vol. 19, Núm. 2, pp. 221-230